S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Having Trouble in Your Trading? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Having Trouble in Your Trading? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Having Trouble in Your Trading? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
Having Trouble in Your Trading? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
NASDAQ:DCPH

Deciphera Pharmaceuticals (DCPH) Stock Forecast, Price & News

$13.50
-0.10 (-0.74%)
(As of 05/31/2023 ET)
Compare
Today's Range
$13.38
$14.30
50-Day Range
$13.28
$15.96
52-Week Range
$10.14
$22.76
Volume
558,097 shs
Average Volume
748,011 shs
Market Capitalization
$1.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.78

Deciphera Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
61.3% Upside
$21.78 Price Target
Short Interest
Bearish
6.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
0.59mentions of Deciphera Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$152,460 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.47) to ($2.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

420th out of 1,006 stocks

Pharmaceutical Preparations Industry

198th out of 492 stocks


DCPH stock logo

About Deciphera Pharmaceuticals (NASDAQ:DCPH) Stock

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.

Receive DCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DCPH Stock News Headlines

Having Trouble in Your Trading?
If you’re having issues in your trading, it could be that it's not you - it really is the market… Well, you’re in control. You can sit on the sideline when it feels right or anticipate massive trend reversals with A.I. like I’ll show you in this upcoming FREE Live A.I. Stock Market Training.
JonesTrading Remains a Hold on Deciphera Pharmaceuticals (DCPH)
Having Trouble in Your Trading?
If you’re having issues in your trading, it could be that it's not you - it really is the market… Well, you’re in control. You can sit on the sideline when it feels right or anticipate massive trend reversals with A.I. like I’ll show you in this upcoming FREE Live A.I. Stock Market Training.
See More Headlines
Receive DCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DCPH Company Calendar

Last Earnings
5/03/2023
Today
6/01/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DCPH
Fax
N/A
Employees
280
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.78
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+61.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-178,930,000.00
Net Margins
-131.38%
Pretax Margin
-130.86%

Debt

Sales & Book Value

Annual Sales
$134.04 million
Book Value
$5.60 per share

Miscellaneous

Free Float
75,046,000
Market Cap
$1.06 billion
Optionable
Optionable
Beta
0.68

Key Executives

  • Steven L. Hoerter
    President, Chief Executive Officer & Director
  • Tucker Kelly
    Chief Financial Officer, Treasurer & Executive VP
  • Daniel L. FlynnDaniel L. Flynn
    Chief Scientific Officer & Executive VP
  • Rodrigo Ruiz Soto
    Senior Vice President-Clinical Development
  • Stephen B. Ruddy
    Chief Technical Officer & SVP













DCPH Stock - Frequently Asked Questions

Should I buy or sell Deciphera Pharmaceuticals stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DCPH shares.
View DCPH analyst ratings
or view top-rated stocks.

What is Deciphera Pharmaceuticals' stock price forecast for 2023?

9 equities research analysts have issued 1 year price targets for Deciphera Pharmaceuticals' stock. Their DCPH share price forecasts range from $9.00 to $30.00. On average, they expect the company's stock price to reach $21.78 in the next year. This suggests a possible upside of 61.3% from the stock's current price.
View analysts price targets for DCPH
or view top-rated stocks among Wall Street analysts.

How have DCPH shares performed in 2023?

Deciphera Pharmaceuticals' stock was trading at $16.39 at the beginning of the year. Since then, DCPH shares have decreased by 17.6% and is now trading at $13.50.
View the best growth stocks for 2023 here
.

Are investors shorting Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 3,750,000 shares, an increase of 10.9% from the April 30th total of 3,380,000 shares. Based on an average daily trading volume, of 649,000 shares, the short-interest ratio is presently 5.8 days. Currently, 7.0% of the company's shares are sold short.
View Deciphera Pharmaceuticals' Short Interest
.

When is Deciphera Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our DCPH earnings forecast
.

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) issued its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.60) EPS for the quarter, hitting analysts' consensus estimates of ($0.60). The firm earned $33.45 million during the quarter, compared to the consensus estimate of $35.50 million. Deciphera Pharmaceuticals had a negative net margin of 131.38% and a negative trailing twelve-month return on equity of 46.56%. The company's quarterly revenue was up 14.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.80) earnings per share.

What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO?

3 employees have rated Deciphera Pharmaceuticals Chief Executive Officer Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among the company's employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

When did Deciphera Pharmaceuticals IPO?

(DCPH) raised $101 million in an IPO on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

What is Deciphera Pharmaceuticals' stock symbol?

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Who are Deciphera Pharmaceuticals' major shareholders?

Deciphera Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.06%), Armistice Capital LLC (5.22%), State Street Corp (4.23%), Braidwell LP (4.13%), Dimensional Fund Advisors LP (1.75%) and Geode Capital Management LLC (1.36%). Insiders that own company stock include Brightstar Associates Llc, Daniel C Martin, Daniel Lee Flynn, Dennis Leo Walsh, Jama Pitman, James Arthur Bristol, Matthew L Sherman, Michael Douglas Taylor, Patricia L Allen, Steven L Hoerter and Thomas Patrick Kelly.
View institutional ownership trends
.

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Deciphera Pharmaceuticals' stock price today?

One share of DCPH stock can currently be purchased for approximately $13.50.

How much money does Deciphera Pharmaceuticals make?

Deciphera Pharmaceuticals (NASDAQ:DCPH) has a market capitalization of $1.06 billion and generates $134.04 million in revenue each year. The company earns $-178,930,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis.

How many employees does Deciphera Pharmaceuticals have?

The company employs 280 workers across the globe.

How can I contact Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The official website for the company is www.deciphera.com. The company can be reached via phone at (781) 209-6400 or via email at eciphera@argotpartners.com.

This page (NASDAQ:DCPH) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -